Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trevena Scores NIH Grant For Research In Major Depression

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech has forged a partnership with NIH to discover and begin development of a biased ligand to the delta opioid receptor for the treatment of MDD.
Advertisement

Related Content

Forest Takes Option On Trevena’s Heart Failure Drug, And Some Equity
Launching Ampyra: The Long Road To Approval
With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure
With $35 Million B Round, Trevena to Push GPCR-Targeted Program into Phase II for Acute Heart Failure

Topics

Advertisement
UsernamePublicRestriction

Register

PS072664

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel